Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Galectin Therapeutics Q3 EPS $(0.24) Misses $(0.16) Estimate;

Author: Benzinga Newsdesk | November 13, 2023 09:23am
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 71.43 percent decrease over losses of $(0.14) per share from the same period last year.

Posted In: GALT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist